Daunorubicin Hydrochloride — Drug Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

13 Recruiting

6 Completed trials

17 Sponsors

24 Countries

Phase III

Phase II

Phase III: 13 Phase II: 4 Phase I/II: 1 Phase IV: 1 Phase I (Other): 1

Oversight events:

3 serious breaches 1 urgent safety measure across 3 trials

View oversight register →

Indications tested

Acute myeloid leukaemia 3 Myelodysplastic syndrome 1

Sponsors using this IMP

Fondazione Gimema Franco Mandelli Onlus 3 Technische Universitat Dresden 2 Charite Universitaetsmedizin Berlin KöR 1 Daiichi Sankyo Inc. 1 GWT-Tud GmbH 1 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. 1 Janssen - Cilag International 1 Kura Oncology Inc. 1 Medical University Of Silesia Katowice Poland 1 Prinses Maxima Centrum voor Kinderoncologie B.V. 1 Robert Bosch Gesellschaft fuer medizinische Forschung mbH 1 Syndax Pharmaceuticals Inc. 1

All trials

20 total

IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending

2023-509392-17-00 Phase III 11 countries Charite Universitaetsmedizin Berlin KöR
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Phase III 13 countries Syndax Pharmaceuticals Inc.
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 Phase III 10 countries Kura Oncology Inc.
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Phase III 15 countries Daiichi Sankyo Inc.
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Phase III 7 countries Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Serial cardiac magnetic resonance imaging (CMR) with contrast agents and biomarker analysis for the detection of cardiotoxicity under anthr… Recruiting

2025-521573-14-00 Phase IV 1 country Robert Bosch Gesellschaft fuer medizinische Forschung mbH
VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study Recruiting

2024-516116-19-00 Phase II 1 country The University Of Birmingham
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Phase II 1 country Technische Universitaet Dresden
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting

2023-504999-25-00 Phase III 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting

2023-510515-19-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 Phase I/II 1 country Technische Universitaet Dresden
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting

2023-505901-17-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years Recruiting

2024-518254-16-00 Phase III 7 countries Vaestra Goetalandsregionen
A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP… Ended

2023-506582-58-00 Phase I (Other) 4 countries Janssen - Cilag International
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended

2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended

2024-515375-35-00 Phase II 2 countries GWT-Tud GmbH
AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended

2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended

2024-515499-12-00 Phase III 12 countries Universita Degli Studi Di Milano Bicocca
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended

2022-502040-13-00 Phase II 1 country University of Leipzig

Showing 1–20 of 20 trials

← All drugs A–Z